Last updated: April 18, 2018
Sponsor: University Hospital Tuebingen
Overall Status: Active - Recruiting
Phase
N/A
Condition
Metastatic Cancer
Treatment
N/AClinical Study ID
NCT03503149
ZPM-001
All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Given informed consent ("broad consent" of the University Hospital Tübingen)
≥ 18 years of age
Clinical indication for a referral to Molecular Tumor Board by the treating physician
Exclusion
Exclusion Criteria:
- The MTB assists the referring physician with the interpretation and the use of tumormolecular profiling data for deciding on a therapeutic strategy. Therefore, this boardis confined to cancer patients and cannot provide any service for non-cancer patients
Study Design
Total Participants: 1000
Study Start date:
March 01, 2018
Estimated Completion Date:
March 01, 2028
Study Description
Connect with a study center
University Hospital Tübingen
Tübingen, BW 72076
GermanyActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.